Protara Therapeutics, Inc. Segments Disclosure
16. Segment Information
The Company’s is the CODM. The CODM allocates resources and assesses performance of the Company’s single reportable segment by regularly reviewing the segment net income (loss) that also is reported on the consolidated statements of operations and comprehensive loss as consolidated net income (loss). The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
The following table sets forth information about the Company’s reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to consolidated net income (loss):
| For the Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Research and development expenses: | ||||||||
| TARA-002 in NMIBC | $ | 18,377 | $ | 12,306 | ||||
| TARA-002 in LMs | 2,606 | 2,558 | ||||||
| IV Choline Chloride | 8,501 | 4,555 | ||||||
| Other research and development | 12,216 | 11,220 | ||||||
| General and administrative expenses | 19,023 | 14,390 | ||||||
| Stock-based compensation expense | 3,826 | 4,125 | ||||||
| Income (loss) from operations | (64,549 | ) | (49,154 | ) | ||||
| Other income (expense), net | 7,110 | 4,558 | ||||||
| Segment net income (loss) | (57,439 | ) | (44,596 | ) | ||||
| Adjustments and reconciling items | ||||||||
| Net income (loss) | $ | (57,439 | ) | $ | (44,596 | ) | ||
Other research and development expenses consist of personnel-related expenses as well as other external research and development expenses that are not directly attributable to a specific program.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 10, 2026 | Showing above |
| 2024 | Mar 5, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.